Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly (NYSE: LLY) will invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.

The project adds advanced oral solid-dose technologies, will support production of orforglipron, and is part of Lilly's previously announced $50 billion U.S. manufacturing capital plan. Lilly estimates up to 1,000 construction jobs and 100 manufacturing jobs. Construction is expected to begin in 2026 with medicine production planned by the end of 2028.

Eli Lilly (NYSE: LLY) and Walmart announced a collaboration to offer Zepbound (tirzepatide) single-dose vials from LillyDirect for in-store pickup at Walmart pharmacies nationwide by mid-November 2025. LillyDirect self-pay pricing offers a 50% or greater discount versus list prices for other GLP-1 obesity medicines, with the 2.5 mg starter dose at $349/month and other doses at $499/month (higher-dose access subject to the Zepbound Self Pay Journey Program). The option supports free home delivery or Walmart pickup and follows rapid LillyDirect uptake, when ~35% of new Zepbound prescriptions were fulfilled through LillyDirect in Q2 2025.

Eli Lilly (NYSE: LLY) announced on October 28, 2025 a collaboration with NVIDIA to build the industry's most powerful pharmaceutical-owned supercomputer: the world's first NVIDIA DGX SuperPOD with DGX B300 systems.

The system is powered by more than 1,000 B300 GPUs on a unified networking fabric and will run an "AI factory" to support discovery, training on millions of experiments, high-volume inference, medical imaging, manufacturing digital twins, and enterprise AI agents. Select models will be shared via Lilly TuneLab. Lilly said the system will run on 100% renewable electricity within existing facilities and use chilled water liquid cooling.

Eli Lilly and Company (NYSE: LLY) announced on October 28, 2025 its roster of seven Team USA athletes for the Olympic and Paralympic Winter Games Milano Cortina 2026, naming Elana Meyers Taylor, Madison Chock, Erin Jackson, Maddie Mastro, Mikaela Shiffrin, Oksana Masters and Jack Wallace.

Lilly reiterated its Milestones into Meaning™ program: for every U.S. Olympic or Paralympic medal, World Record or Olympic/Paralympic Record, Lilly will donate $5,000 to U.S. nonprofits that expand health care access. The program donated $2.6 million to 24 organizations at Paris 2024 and will expand to benefit 26 U.S. organizations in Milano Cortina 2026.

Eli Lilly (NYSE: LLY) announced on October 27, 2025 that the U.S. FDA approved a single‑injection, once‑monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab‑mrkz) for adults with moderately to severely active ulcerative colitis.

The approval follows an EU authorization and is supported by a Phase 1 bioequivalence study comparing one 200 mg/2 mL injection to two 100 mg/1 mL injections. The single‑injection, citrate‑free maintenance dose will be available in the U.S. via prefilled pen or syringe in early 2026. Omvoh retains existing safety warnings for allergic reactions, infections, and liver problems.

Eli Lilly and Company (NYSE: LLY) declared a fourth-quarter 2025 dividend of $1.50 per share on outstanding common stock.

The dividend is payable on December 10, 2025 to shareholders of record at the close of business on November 14, 2025.

Eli Lilly (NYSE: LLY) announced on Oct 27, 2025 a nationwide partnership with Shaquille O'Neal to expand the "Don't Sleep on OSA" campaign and raise awareness of moderate-to-severe obstructive sleep apnea (OSA).

The initiative highlights that an estimated 24 million U.S. adults may have OSA, outlines common symptoms (loud snoring, choking/gasping, daytime sleepiness), and directs people to DontSleepOnOSA.com to learn more and talk to their healthcare provider.

Eli Lilly (NYSE: LLY) reported Phase 3b LUCENT-URGE results showing early, sustained improvement in bowel urgency for adults with moderately to severely active ulcerative colitis treated with Omvoh (mirikizumab‑mrkz).

Key outcomes: 55% reduction in daily bowel urgency episodes by Week 12 (maintained at Week 28), 52% reduction in urgency severity by Week 28, and increase in patients able to delay a bowel movement ≥15 minutes from 4.1% at baseline to 29.7% at Week 28. Safety was consistent with prior LUCENT data: 5.2% serious adverse events and 4.7% discontinuations due to adverse events. Results will be presented at ACG Oct 24–29, 2025.

Eli Lilly (NYSE:LLY) agreed to acquire Adverum Biotechnologies for $3.56 cash per share plus one CVR, with the CVR payable up to $8.91 for total potential consideration of $12.47 per share. The deal funds a tender offer and a second-step merger, is expected to close in Q4 2025, and requires a majority tender. Lilly provided a secured $65 million promissory note to support Adverum operations pre-close. Adverum's lead asset, Ixo-vec, is a Phase 3 intravitreal gene therapy for wet AMD (ARTEMIS trial completed screening) with Fast Track, RMAT, EMA PRIME, and UK Innovation Passport designations.